Clinical Evidence Library
Clinical evidence from guidelines, trials, biomedi…
PCOS guidelines: what changed from 2018 to 2023?. Walk readers through the shift from 2018 to 2023 as refinement rather than reversal. Emphasize streamlined diagnosis, AMH as an adult-only ultrasound alternative, broader cardiometabolic and psychological risk recognition, and the continued low-to-moderate evidence base.
Did the 2023 PCOS guideline change everything? Not really. It builds on 2018 with the same evidence-based core, just a cleaner diagnostic pathway and broader recognition of what PCOS affects[[cite:1]]. The biggest diagnostic shift is refinement: adults still use the established framework, but 2023 s...
ViewClinicalTrials.gov results: useful evidence or reporting trap?. Synthesize what the results database adds to journal publications, then assess major interpretation risks including self reporting, missing fields, inconsistent entries, imprecise outcome definitions, incomplete participant result reporting, and incomplete registry coverage. Include a compact table separating what reviewers can extract, what they should verify, and what should be treated cautiously.
ClinicalTrials.gov as evidence for semaglutide vs tirzepatide weight loss ClinicalTrials.gov is best treated as a **complement** to journal publications, not a replacement. For semaglutide and tirzepatide weight-loss comparisons, it can add protocol-level details and posted summary results, but it d...
ViewFast facts on ClinicalTrials.gov results quality. Build five cards around the strongest quantitative and interpretive findings: 79,413 registry records, 2,178 posted results records, 20 percent with more than two primary outcomes, 61 percent lacking specificity in planned analysis metric, and the self reported nature of the data. Frame the deck as historical quality signals rather than current registry performance.
This is a retrospective look at registry quality signals in ClinicalTrials.gov, not a report of current performance. The registry-record analysis examined 79,413 ClinicalTrials.gov records. In the planned-analysis sample, 61% of first primary outcome entries were too vague to identify a measurement ...
ViewCan AI safely accelerate evidence synthesis?. Build a knowledge-check quiz around what AI tools can and cannot reliably do in systematic review workflows and evidence-disagreement detection. Include items on screening, data extraction, risk-of-bias assessment, human validation, selective reporting, and fine-grained population extraction failures.
Q1. According to the systematic review, which task did AI methods appear to be used for most often in evidence synthesis workflows? - Study screening - Data extraction - Risk-of-bias assessment - Selective reporting detection Answer: Study screening[[cite:1]] Q2. What did the review say about the re...
ViewWhy GLP-1 discontinuation matters for evidence interpretation. Produce a sub two minute narrated explanation that separates trial efficacy from persistence and tolerability in practice. Close with the evidence-review question of whether outcomes are durable when treatment is stopped or doses differ from trial protocols.
When comparing semaglutide and tirzepatide for weight loss, it matters whether we are looking at trial efficacy or real-world use. Trials test ideal dosing and steady treatment, but in practice many patients stop early, stay on treatment inconsistently, or use lower doses than the trials studied. Th...
ViewIs 80 percent medication adherence an evidence-based threshold?. Create a short professional thread that explains the historical 80 percent threshold, the systematic review finding that thresholds vary by condition and outcome, and the limits caused by heterogeneous measures. End with implications for evidence reviewers who need to pre-specify adherence definitions.
Is 80% medication adherence really a universal cutoff? The review says that number came from an early empirical definition in antihypertensive care, where taking at least 80% was treated as sufficient[[cite:1]]. But the authors do not treat 80% as a proven standard. They say they could not reject or...
View- 1(current)